Loading…
Loading…
Important Notice Regarding Alleged Regulatory Approval Misrepresentations in the Compass-Anywhere Merger. The lawsuit claims the offering materials promised "reasonable best efforts" through ordinary channels while Compass allegedly used a politically connected backchannel to senior DOJ officials.
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place in Colorado Springs, CO, from November 5-8. The Company will feature its Change the Tune in TRD educational campaign for U.S. HCPs focused on TRD, as well as encore presentations from its COMP360.
COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027. COMPASS is initially targeting the TRD market, which is large and underserved. SPRAVATO has already established the commercial potential of this market, and COMP360 could benefit from reduced dosing frequency. Recent industry M&A also validates the commercial potential of psychedelics, although competitive dynamics and reimbursement are key risks.
NEW YORK--(BUSINESS WIRE)---- $COMP #ClassActionLawsuit--If you have suffered a loss on your Compass, Inc. (“Compass” or the “Company”) (NYSE: HOUS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until December 7, 2026 to ask the Court to appoint them as lead plaintiff.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]What Is The Lawsuit About?.
New class action for Compass, Inc. (COMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 12/7/2026
Class action covers investors who bought Compass, Inc. securities between January 9, 2026 and October 7, 2026; complaint alleges the company failed to disclose material adverse facts Class action covers investors who bought Compass, Inc. securities between January 9, 2026 and October 7, 2026; complaint alleges the company failed to disclose material adverse facts
LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Compass, Inc. (“Compass” or “the Company”) (NYSE: COMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of COMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Disclosure Under Scrutiny: Compass's merger risk factors allegedly described antitrust enforcement as a risk that "may" or "could" occur. The lawsuit says the materials omitted a DOJ backchannel that was already in motion Disclosure Under Scrutiny: Compass's merger risk factors allegedly described antitrust enforcement as a risk that "may" or "could" occur. The lawsuit says the materials omitted a DOJ backchannel that was already in motion
No recent filings indexed.